Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
49 United States sites
5 France sites
5 Spain sites
4 Greece sites
4 Italy sites
4 United Kingdom sites
3 Canada sites
2 Lebanon sites
2 Germany sites
12 Years - 65 Years
Phase 2/Phase 3
The iPeer2Peer Sickle Cell Disease (SCD) study matches youth (12-18 years of age) with SCD to a mentor (trained young adult) who has learned to manage their SCD well, transitioned to adult care, and can support youth participants emotionally and socially.
3 Canada sites
1 United States site
12 Years - 18 Years
Not Applicable
This study aims to enroll 58 pre-adolescent (<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor.
11 United States sites
2 Years - 13 Years
HbSS
Phase 2
The goal of the study is to evaluate the efficacy and safety of crizanlizumab in SCD patients with priapism.
19 United States sites
> 16 Years
HbSS, HbSC
Phase 2
This study will compare the effectiveness of two self-management support interventions-Community Health Workers (CHW) and mobile health (mHealth)-versus enhanced usual care to improve health-related quality of life and acute care use for transitioning youth with sickle cell disease (SCD), and identify and quantify mediators and moderators of intervention treatment effects.
5 United States sites
> 17 Years
HbSS, HbSC, HbSβ0Thal
Not Applicable
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
2 United States sites
1 Day - 21 Years
Phase 1/Phase 2
